# Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

> **NCT06596694** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 180 (estimated)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **BIOLOGICAL:** Patritumab deruxtecan

## Key facts

- **NCT ID:** NCT06596694
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-03
- **Primary completion:** 2028-12-07
- **Final completion:** 2028-12-07
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06596694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06596694, "Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06596694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*